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Background: Hemostatic agents, tissue adhesives and sealants may contribute to a reduction in hemorrhage-associated
morbidity and mortality. Towards this end, we have recently developed a lysine-based dendritic hydrogel (PEG-LysNH2)
that can potentially be used in the management of severe trauma and/or intraoperative bleeding. As a first step
in demonstrating the potential utility of this approach, our objective was to ascertain the ability of the PEG-LysNH2 to
adhere to and seal injured tissues, as well as to maintain the seal under physiological conditions.
Methods: The efficacy of the PEG-LysNH2 in sealing injured tissues was evaluated using an ex-vivo pressure testing
system. A 2.5 mm incision was made on intact ex-vivo tissues and then sealed with the PEG-LysNH2. Application
of the PEG-LysNH2 was followed by 1) step-wise pressure increase to a maximum of 250 mmHg and 2) fluctuating
pressures, between 100–180 mmHg with a rate of 3 Hz, over a 24-hour period. The performance of the PEG-LysNH2
was compared to those of commercially available sealants and adhesives.
Results: During gradual pressure increase, mean pressures at 30 seconds (P30) ranged between 206.36 - 220.17 mmHg
for the sealants, and they were greater than control and suture groups (p < 0.01 and p = 0.013, respectively). Additionally,
all products held under fluctuating pressures: mean pressures ranged between 135.20 - 160.09 mmHg, and there were
no differences observed between groups (p = 0.96).
Conclusions: The efficacy of the PEG-LysNH2 was significantly superior to conventional injury repair methods (sutures)
and did not differ from those of commercially available products when sealing small incisions.
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In the surgical setting, intraoperative bleeding that is
unresponsive to conventional methods is associated
with prolonged surgery times and significantly contributes
to postoperative complications [1]. Topical hemostatic
agents, sealants, and adhesives may be used during surgi-
cal procedures to achieve hemostasis when hemorrhage
is not controlled by standard methods such as direct* Correspondence: anazaria@bidmc.harvard.edu
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article, unless otherwise stated.pressure, vessel ligation, and suturing [2]. These prod-
ucts physically adhere to damaged tissues and seal
injured blood vessels to prevent further blood loss [3].
Additionally, specific agents may accelerate the produc-
tion of a fibrin thrombus by activating the coagulation
cascade [4].
We have recently developed a lysine-based dendritic
hydrogel (PEG-LysNH2) that can potentially be used in
the management of severe trauma and/or intraoperative
bleeding [5]. As a first step in demonstrating the potential
utility of the PEG-LysNH2, it was necessary to ascertain
its ability to adhere to and seal injured tissues, as well as
to maintain the seal under physiological conditions. WeCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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sure testing in the absence of direct pressure by adhering
to damaged tissue, and that its performance would be sig-
nificantly better than that of conventional sutures and
non-inferior to those of commercially available hemostatic
agents, tissue adhesives and sealants.
Methods
Synthesis of the PEG-LysNH2
The PEG-LysNH2 was synthesized using a previously
reported procedure [5]. Briefly, a solution of pegylated ly-
sine dendron 1 in borate buffer at pH 9 was reacted with a
solution of poly(ethylene glycol disuccinimidyl valerate) of
3400 MW (2, SVA-PEG-SVA) in PBS buffer at pH 6.5
(Figure 1). The ratio of amine to SVA was 1:1, and the total
concentration of polymer in solution was 30 wt%. A hydro-
philic gel formed spontaneously within seconds upon mix-
ing the two aqueous solutions.
Rheological characterization
For each test material, cylindrical samples with a 9 mm
diameter and 3 mm thickness were prepared in a precast
Teflon mold and analyzed using 8 mm steel plate geometry.
The mechanical strength and viscoelastic properties of the
materials were investigated using dynamic rheological mea-
surements and the frequency sweeps of all sealants and ad-
hesives were measured at a frequency of 0.1 to 10 Hz with
a controlled oscillatory stress of 50 Pa and at 20 °C (RA
1000, TA Instruments - New Castle, DE, USA) [5]. The
shear storage (G’) and shear loss (G”) describe the elastic or
solid-like and viscous or liquid-like characteristics, respect-
ively, of a material. G’ values were reported as mean ± SEM
(n = 3) for all sealants and adhesives, at 1 Hz of frequency
and 50 Pa of oscillatory stress.
Pressure testing
The testing device consisted of a sensor assembly con-
nected to a cylindrical reservoir (Figure 2). The sensor
assembly contained a flow sensor (FLR-1007, Omega En-
gineering - Stamford, CT, USA) as well as a pressure sensor
(PX-309, Omega Engineering - Stamford, CT, USA), whichFigure 1 Formation of PEG-LysNH2 upon mixing of dendron 1 with SVA-Pacquired data at a per-second rate and sent it to a data
logger (DAQPRO-5300, Omega Engineering - Stamford,
CT, USA). The sensor assembly was connected to the
reservoir through polyvinyl chloride (PVC) pressure
monitoring lines (MX561, Smiths Medical - Dublin, OH,
USA) creating a closed system. The reservoir was lined
with ex-vivo tissues (bovine aorta or murine skin) (Figure 2b),
and 0.9% sodium chloride solution was fed into the system
in either a continuous or pulsatile fashion - to simulate
venous and arterial bleeding - using either a pressure
infusor (Infusable, Vital Signs Inc. - Totowa, NJ, USA)
or a peristaltic pump (SP04 L, Otto Huber GmbH -
Böttingen, Germany).
We compared the efficacy of the PEG-LysNH2 to those
of commercially available agents (Table 1). In order to
comply with the original indications of the products, effi-
cacy was tested on small wounds under dry conditions.
Agents designed for vascular hemorrhage control were
tested on bovine aortas, whereas topical agents were tested
on murine skins. The PEG-LysNH2 was tested on both
tissue types. All tissues used in the study were fresh frozen,
preserved at −20°C and thawed for 30 minutes before test-
ing. All products were applied directly on the wound in
multiple thin layers with syringe or “gun” dispensers.
Mixture of the products took place on the dispenser
(Dermabond, Omnex, PEG-LysNH2), the dispenser tip
(BioGlue) or directly on the wound surface (Evicel).
Only one application was attempted in all trials.
Resistance to failure
A 2.5 mm incision was made on the otherwise intact
tissues and then sealed with the products (n = 3 per
group). Three control groups were included in the tests:
1) intact tissue, 2) incised tissues without sealing and 3)
incised tissues repaired with sutures (two vertical mattress
suture stitches with an approximate bite size of 3 mm for
the large bite and 1.5 mm for the small bite) using 4–0
polypropylene. After 10 minutes, pressure within the
system was increased, in a stepwise fashion, by 40 mmHg
every 5 seconds to a maximum of 250 mmHg, or
until failure (noted by a sudden drop in pressureEG-SVA 2. Hydrogel dyed with green food coloring.
Figure 2 The failure testing device. a. Schematic representation of the testing device. Arrows indicate the direction of flow within the system; b.
Photograph of the EVAH testing device. Saline solution was fed into the system with an infusor or a peristaltic pump (not shown).
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leakage of saline through the wound). Mean pressure in
the system at 30 seconds (P30) was calculated and com-
pared between groups using one-way analysis of vari-
ance (ANOVA). Bonferroni corrected, two-tailed p
values were used to establish statistically significant dif-
ferences using α = 0.05 as the initial criterion. Relative
standard error was calculated as an index of measure-
ment reproducibility. Power calculations which indi-
cated that 3 experiments would provide 88.1% power
(β = 0.881) to detect a difference of 25 mmHg between
treatment groups (δ = 25 mmHg) using the standard
deviation of P30 intact tissue (σ = 7.31 mmHg).
Endurance
We assessed the capacity of the products to hold and
withstand fluctuating pressures analogous to human
arterial pressures. A 2.5 mm incision was made on the
otherwise intact tissue and then sealed with the
products (n = 3 per group). A control group, of intact
tissues only (without incisions) was included in this
experimental phase. After 10 minutes, the system was
subjected to fluctuating pressures (between 100 and
180 mmHg) with a rate of three cycles per second (Hz).
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[5] - hemostasisand compared between groups using one-way ANOVA.
Bonferroni corrected, two-tailed p values were used to
establish statistically significant differences using α =
0.05 as the initial criterion.
Results
Use and rheological properties
Rheological measurements showed that all materials ex-
hibited shear storage moduli (G’) greater than shear loss
moduli (G”), at all frequencies and 50 Pa oscillatory
stress, indicating that the samples are more elastic than
viscous (Figure 3). At 1 Hz, Dermabond exhibited the
highest G’ value (1.51 × 107 Pa) followed by BioGlue
(2.04 × 106 Pa), Omnex (2.47 × 105 Pa), PEG-LysNH2
(1.16 × 104 Pa) and Evicel (3.7 × 103 Pa). Samples exhi-
biting high G’ (e.g. Dermabond, BioGlue and Omnex)
(Figure 3A) were stiffer than the samples with lower G’
(e.g. PEG-LysNH2 and Evicel) (Figure 3B), likely due to
an increase in the cross-link density of their formed
network. The loss tangent values (tan δ = G”/G’) were
lower than 1 for all materials at the investigated fre-
quency of 1 Hz (tan δ = 0.2, 0.05, 0.7, 0.04, and 0.3 for
Dermabond, BioGlue, Omnex, PEG-LysNH2, and Evicel,
respectively, at 1 Hz) with smaller tan δ values indicating
a more solid-like material.y
action
ross-links bovine albumin to cell proteins at wound site to form a tough
ibrinogen mixed at site of application; thrombin cleaves fibrinogen to
rin [2].
rs that rapidly form polymers in the presence of water and thereby quickly
ether [2].
rs that rapidly form polymers in the presence of water and thereby quickly
ether [2].
hydrogel forms an adhesive physical barrier on the wound’s surface
is not dependent on the clotting cascade.
Figure 3 Frequency sweeps of various sealants and adhesives at 1 Hz of frequency, 50 Pa of oscillatory stress and 20°C. a. Dermabond, Bioglue
and Omnex. b. Evicel and PEG-LysNH2.
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When applied to 2.5 mm incisions under dry conditions,
all products withstood pressures greater than 250 mmHg
without signs of failure or leakage. P30 in sealed groups
ranged between 206.36 - 220.17 mmHg and no statisti-
cally significant differences were observed between the
groups (p = 0.94) (Figure 4). The control and suture
groups had lower mean P30, when compared to sealed
groups, as the pressure increase was hindered by active
fluid loss (p < 0.001 for control and p = 0.013 for suture,
Bonferroni-corrected α = 0.025 for 2 tests). The average
relative standard error for the P30 measurements was
4.97 ± 1.84%.Endurance
All products held the shear stresses of fluctuating pres-
sures for a 24-hour period. Mean pressures rangedFigure 4 Resistance to failure. Pressure was gradually increased within the
reported for each group. Asterisks (*) denote statistically significant differenbetween 135.20 - 160.09 mmHg, and there were no dif-
ferences between the products or between the products
and the control group composed of intact tissues (p =
0.96) (Figure 5). The novel PEG-LysNH2 was able to seal
the incisions in both ex-vivo vascular and dermal tissues.Discussion
Sealants, adhesives and hemostatic agents are useful ad-
juncts to surgical care, as they can reduce operative
times, improve the quality of surgical tissue manage-
ment, and decrease bleeding [2]. Applications for these
agents include wound closure in skin and mucosal sur-
faces, sealing of intestinal and vascular anastomoses,
prevention of cerebrospinal fluid leakage, fixation of surgi-
cal devices and grafts and hemorrhage control across all
surgical specialties [2,6–8]. Products with new properties,
such as the ability to deliver antimicrobial medications orsystem and measured at 30 seconds (P30). Mean pressure values are
ces after ANOVA with Bonferroni correction.
Figure 5 Endurance. The sealed wounds were subjected to alternating pressures for a 24-hour period. Mean pressure values are annotated for
each group.
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of the injury and sparing the need for debridement [5],
could further reduce morbidity and improve patient
outcomes.
Even though animal experimentation plays a fundamen-
tal role in the development of sealants, adhesives and
hemostatic agents, the efficacy of new materials and
formulations should be evaluated before proceeding to
testing in animal hemorrhage models. Researchers
should replace, reduce and refine [9,10] the use of
animal models whenever possible; ex-vivo pressure testing
offers an alternative to animal models and a means to
optimize development. In order to reduce the number of
animal experiments and in accordance with the guiding
principles for the ethical use of animals in testing
[9,10] we conducted this study in a simulated model
of hemorrhage using ex-vivo tissues. A similar approach
has been used to evaluate the strength of sealants used in
the repair of cerebrospinal fluid leak [11].
The adhesives and sealants used in this study, exhibit-
ing different dynamic mechanical strength ranging from
stiff to rigid, were subsequently tested in an ex-vivo
model of venous and arterial hemorrhage to determine
their wound-closure performance. Although the mate-
rials exhibited different dynamic mechanical properties,
they were able to seal ex-vivo injuries and withstand
physiological pressures: furthermore, their efficacy was
superior to that of simple suturing techniques. In particu-
lar, the PEG-LysNH2, a novel sealant in the initial phases
of development, was included in our tests: its performance
did not differ from those of previously approved sealants
and adhesives, and it was also superior to simple sutures,
thus confirming its sealant efficacy for small ex-vivo arter-
ial injuries under pressures of up to 250 mmHg and for
periods up to 24 hours.An ideal surgical tissue adhesive or sealant should
exhibit rapid adhesion to injured tissues and maintain
strong and close apposition of wound edges for an
amount of time sufficient to allow wound healing
[12,13]. An ideal hemostatic agent should meet the re-
quirements for tissue adhesives and also exhibit the
following additional properties: 1) stop hemorrhage
from actively bleeding vessels; 2) maintain physiological
pressures for several hours; and 3) be easily applied to the
tissue with a user-friendly procedure [14]. Thus far, the
PEG-LysNH2 has demonstrated to be adherent to ex-vivo
tissues, resistant and easily applied, but it has yet to prove
its efficacy in controlling active hemorrhage in in-vivo
models of hemorrhage. In subsequent development stages,
and in order to evaluate the efficacy of the PEG-LysNH2
as a hemostatic agent, we will assess its efficacy in a
well-established small animal model of uncontrolled
hemorrhage [15], and, if successful, proceed to a large
animal model: the logical steps in the design or evalu-
ation of new hemostatic agent formulations.
Several limitations are evident when testing the efficacy
of the PEG-LysNH2 using the proposed ex-vivo model. As
it is presented in this study, the model is unable to assess
the efficacy of hemostatic agents, as their basic mechan-
ism of action relies on the activity of the clotting cascade.
Additionally, physiologic outcomes such as survival, mean
arterial pressure resuscitation fluid usage are often used to
evaluate hemostatic agent efficacy [16]. To date, no
ex-vivo model has been able to simulate the actual
pathophysiologic response to injury and stress, making
animal models irreplaceable in subsequent stages of
product development. Therefore, with this study’s re-
sults it is only valid to conclude that the PEG-LysNH2
meets the basic requirement of a tissue adhesive or
sealant: it physically adheres to and seals injured
Villa-Camacho et al. BMC Musculoskeletal Disorders  (2015) 16:116 Page 6 of 6tissues, thereby preventing fluid loss in a physiologic
pressure range.
Conclusion
In conclusion, all the products evaluated in this study -
including the novel PEG-LysNH2 - were able to seal
small incisions in ex-vivo skin and vascular tissues with
better outcomes than simple suture repairs. These en-
couraging preliminary results on the efficacy of the
PEG-LysNH2 show that it meets the basic requirements
of tissue adhesives and sealants. In order to justify its
use as a hemostatic agent in emergent care scenarios,
further research regarding the performance of this novel
sealant in in-vivo models of uncontrolled hemorrhage is
necessary.
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